





15th Annual Outsourcing in Clinical Trials New England 2023

John B. Hynes Veterans Memorial Convention Centre, Boston

1st-2nd November 2023 www.arena-international.com/octnewengland/



The 15th Annual Outsourcing in Clinical Trials New England event will bring together clinical trial professionals from big and small biopharma to uncover new technologies and processes, to optimize their clinical and outsourcing operations.

2023 Speakers

- Hollie Schmidt, Vice President, Scientific Operations, Accelerated Cure Project for MS
- Adrienne Gaggi, Associate Director, Clinical Development, Aldeyra Therapeutics
- Deborah Howe, Director, Global Patient Recruitment and Engagement, Alexion
- Rohita Sharma, PhD, Global Senior Director, LEAP Lead, Patient Insights and Solutions, Medical Affairs, Alexion
- Shelby Abel-Kilmartin, Director, Data Management Strategic Outsourcing and Vendor Management, Alexion, AstraZeneca Rare Disease
- Joyce Moore, Global Head of Patient Engagement, Allucent
- Marilyn Fontaine, Director, Clinical Operations, AnHeart Therapeutics
- Claudia Hesselmann, PhD, Founder and Chief Executive Officer, ARENSIA
- Tola Olorunnisola, Senior Vice President, Clinical Services and Strategy, Avantor
- Siddharth Parulkar, Senior Director, Head of Clinical Operations, Aprinoia Therapeutics
- Kevin Ahonen, Former Head of Digital Engagement, Biogen
- Behtash Bahador, Director, Health Literacy, CISCRP
- Sarah Tressel Gary, Senior Scientific Advisor, eCOA Clinical Science and Consulting, Clario
- Cathleen Platt, Vice President, Clinical Operations, Click Therapeutics
- Jodi Coughlin, Director, Vendor Relationship Management, Deciphera Pharmaceuticals
- Stacey Limauro, Executive Director, Clinical Operations, Deciphera Pharmaceuticals
- Holly Huang, Vice President, Head of Biometrics, Denovo Biopharma
- Ritu Mehta, Director, Business Development, DP Clinical
- Jason Konn, Solution Consultant, eClinical Solutions
- Jenny Bentsen Gordon, Vice President, Head of Clinical Operations, Editas Medicine
- Christine Slater, Associate Director, Patient Recruitment, Editas Medicine
- Colleen Graham, Vice President, Head of Clinical Operations, Mediar Therapeutics
- Ching Tian, Chief Innovation Officer, Emmes
- Neha Ghosh, Associate Director, Clinical Research, Fresenius Medical Care
- Amanda Murphy, Senior Director, Data Intelligence and Solutions, GlobalData
- Vikas Agarwal, Vice President, Head of Program Development, Greenfire Bio

- Blake E Wilson, Partner, Hogan Lovells LLP
- Chris Cain, Vice President, Clinical and Regulatory Affairs, Hyalex Orthopaedics
- Missy Hansen, Paediatric Strategy Liaison, ICON Plc
- Kelsey Miller, Director, Clinical Development, Intrinsic Therapeutics
- Stuart Thiede, Vice President and General Manager, Clinical Trial Payments, IQVIA Technologies
- Leonella Seeley, Associate Director of Vendor Management and Operations, Karyopharm
- Judith Murphy, Executive Director, Centralized Contracting and Outsourcing, Kura Oncology
- David Sherris, Board Member, Kurve Therapeutics
- Harry Barnett, Executive Chairman, Lubris Biopharma
- Ken Hamill, Senior Director, Clinical Operations Portfolio, Medidata
- Kelly McKee, Vice President, DCTs and Patient Registries, Medidata
- Tom Gottschalk, Senior Director, Business Development, Mercalis
- Mackenzie Johnson, Senior Manager, Patient Centricity, Moderna
- Jessica Perry, Director, Patient Centricity, Clinical Innovation, Moderna
- Leticia Tarilonte, Senior Director, Clinical Operations Consultant, Nimbus Therapeutics
- Rana Said, Biomarker Study Coordinator, Novartis
- Kathryn Duschean, Senior Scientist, Laboratory Excellence and Operations, Novartis
- Alyce King, Associate Director, Business Development, Novotech
- Donna Fraser, Director, Client Operations, Novotech
- Nan Doyle, Patient Advocate
- Chris Weiss, Vice President, Sales, OpenClinica
- Prasanna Rao, Senior Director, Global Head of Al and ML, Pfizer
- Stacey Oppenheimer, Imaging Vendor Oversight and Sourcing Strategy Lead, Pfizer
- Douglas Henry, President, Phazemos
- Robert Loll, Senior Vice President, Business Development and Strategic Planning, Praxis
- Nicole Stansbury, SVP and Head of Global Clinical Operations, Premier Research
- David Hadden, President, Founder and Chief Game Changer, Pro-ficiency
- Christine Hurley, VP, Clinical Business Operations and Innovation, Relay Therapeutics
- Emily Matthews, Senior Manager, Clinical Business Operations, Relay Therapeutics
- John J Seman, Chief Executive Officer, Revitale Pharma
- Shari Coslett, Vice President, Clinical Operations, Rhythm Pharmaceuticals
- Steven Cummings, Executive Director, San Francisco Coordinating Center, California Pacific Medical Center Research Institute
- Rinaldo Dorman, MBA, CPSM, Associate Director, R&D Global Procurement & Strategic Sourcing, Sarepta Therapeutics
- Dima Hendricks, Sickle Cell Patient Advocate
- Ivor Clarke, Chief Innovation Officer, SubjectWell
- Jim Palma, Executive Director, TargetCancer Foundation
- Nissa Ashenbramer, Senior Project Manager, Oncology and Hematology, TFS Health Science
- Meredith Frank-Molnia, Senior Director, Clinical Operations, Third Pole Therapeutics
- Hope Weisser, Senior Product Manager, TransPerfect
- April Mattison-Wolfe, Senior Solutions Architect, TransPerfect
- Ken Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development,
 Tufts University School of Medicine
- Mary Jo Lamberti, Research Associate Professor and Director, Sponsored Research, Tufts
 Center for the Study of Drug Development
- Sverre Bengtsson, Co-Founder, Senior Vice President Strategic Relations, Viedoc



- Mike Waters, Global Vice President Biopharma Business Development, Cerba Research
- Amy Raymond, PhD, PMP, Therapeutic Strategy Lead, Gene Therapy Think Tank, Worldwide Clinical Trials
- Lisa Kang, Head, Clinical Development Operation, Yoda Pharmaceuticals
- Evan Hahn, Senior Vice President, IRT Solutions, YPrime

Outsourcing in Clinical Trials New England DAY 1 – Wednesday 1st November			
7:30am	Registration and refreshments		
8:20am	Chairperson's opening remarks Amanda Murphy, Senior Director, Data Intelligence and Solutions, GlobalData		
8:30am	 OPENING KEYNOTE: Innovation in the US pharma industry: uncovering challenges and opportunities Harnessing the power of language models such as GPT to revolutionize pharma innovation The potential of advanced technology to drive advancements in drug discovery, optimize clinical trials and enable personalized medicine Practical takeaways: how you can leverage AI and Generative AI to achieve transformative innovation in your clinical trial Prasanna Rao, Senior Director, Global Head of AI and ML, Pfizer 		
9:00am	 Solving the clinical data challenge Patient centricity requires data centricity to integrate and manage a growing variety of data sources. The challenge lies in integrating and managing those sources to deliver high-quality data. How do we overcome this? Moving from manual, reactive data review and cleaning to proactive, risk-based approaches based on integrated data Providing clinical data management and monitoring teams with workflows and analytics that support their day-to-day functions Leveraging technologies that incorporate AI to automate manual tasks and identify potential issues sooner Ken Hamill, Senior Director, Clinical Operations Portfolio, Medidata 		
9:30am	PATIENT ADVOCACY KEYNOTE: Patient experience in oncology trials: lessons learned from a patient advocacy-driven, decentralized clinical trial How easy and accessible are oncology trials to patients, and where are the main hurdles? What do pharma and biotech sponsors need to be doing in order to ensure a reduced burden on patients participating in clinical trials? Decentralized clinical trials: and what are the benefits and challenges of incorporating elements of decentralization into your clinical trial from a patient perspective? Jim Palma, Executive Director, TargetCancer Foundation		
10:00am	Perspectives on the biotech/CRO investment landscape Perspective on investment landscape Biotech workforce current trends and the implications for clinical trials M&A activity in the CRO landscape and how that impacts sponsors Alyce King, Associate Director, Business Development, Novotech		
10:30am	Morning refreshments and networking break		



	Stream A: Clinical Outsourcing and Operations	Stream B: Clinical Technology and Innovation	Stream C: Patient Recruitment and Engagement
	Chair: Amanda Murphy, Senior Director, Data Intelligence and Solutions, GlobalData	Chair: Meredith Frank-Molnia, Senior Director, Clinical Operations, Third Pole Therapeutics	Chair: Robert Loll, Senior Vice President, Business Development and Strategic Planning, Praxis
11:00am	Choosing a vendor as a small biotech: creating a hierarchy of considerations • What are the most important factors when selecting vendors and CROs for your clinical trial? • Is it always crucial to have trial partners with expertise in your therapeutic area? • Should cost be the primary factor in vendor selection? Jodi Coughlin, Director, Vendor Relationship Management, Deciphera Pharmaceuticals Stacey Limauro, Executive Director, Clinical Operations, Deciphera Pharmaceuticals	Incorporating real world evidence into clinical trials: what new opportunities are created? • Tapping into the full potential of real world evidence and incorporating this into your trial • Barriers to adopting real world evidence: how to address and overcome these • Navigating regulations in the USA in relation to the use of real world evidence in clinical trials Lisa Kang, Head, Clinical Development Operation, Yoda Pharmaceuticals	PANEL DISCUSSION: Navigating new regulations around diversity and inclusion The importance of ensuring your patient population is diverse Strategies to improve diversity, equity and inclusion in your trial Building trust and relationships with communities who may not traditionally participate in clinical trials Innovative methods of engaging with the wider patient community Best practice in working closely with patient advocacy groups MODERATOR: Behtash Bahador, Director, Health Literacy, CISCRP PANELLISTS: Blake E Wilson, Partner, Hogan Lovells LLP Cathleen Platt, Vice President, Clinical Operations, Click Therapeutics Marilyn Fontaine, Director, Clinical Operations, AnHeart Therapeutics Missy Hansen, Paediatric Strategy Liaison, ICON PIc
11:30am	Simplifying protocols to enable home-base trial activities • How simplification of a protocol for Parkinson's disease enabled a home-based trial • Lean Design approach to radical simplification: results for Merck protocols • Overcoming resistance to simplification: common issues	TECHNOLOGY SPOTLIGHT: Running up that hill: accelerate cycle times and reach patients faster with elluminate Learn how elluminate and eClinical's Biometrics Services deliver: Operational insights across numerous data sources that provides definitive answers and analytics on enrollment, protocol compliance and safety	Accelerated performance of complex exploratory patient studies: practical insights from investigational site • Global challenges and industry trends • Research clinics dedicated to early patient trials • Key elements to consider when planning a Phase Ib/IIa patient trial



Steven Cummings, Executive
Director, San Francisco
Coordinating Center, California
Pacific Medical Center Research
Institute

- Improved study oversight with a holistic view of risk across all data sources
- 50 out-of-the-box visualizations to support cross-study analysis for deeper insights with selfservice access to clinical and operational analytics
- Increased productivity across data management, medical monitoring, clinical operations, clinical programming and statistical analysis roles

Jason Konn, Solution Consultant, eClinical Solutions

TECHNOLOGY SPOTLIGHT:
eSource: auto-populate eCRFs
with source data on study Day 1
Learn how eSource, EHR-to-EDC
integration automatically populates
eCRFs on study day one with
source data. We'll discuss
practicality, implementation and
scalability so you can see how we're
keeping patients at the center of
clinical trials with proven solutions
that lessen the burden for
researchers, sponsors and patients
alike. Join this session and learn
how to:

- Get source data on study Day 1
- Ease the burden with smart, automated workflows
- Simplify enrollment, data sharing and participation
- Enhance decision support for site and sponsor stakeholders
- Improve recruitment and retention with engaging digital solutions

Chris Weiss, Vice President, Sales, OpenClinica

Case studies
 Claudia Hesselmann, PhD,
 Founder and Chief Executive
 Officer, ARENSIA

The state of the biopharmaceutical industry: midyear update and 2024 outlook

- Reviewing results from our annual survey - were the 2023 predictions correct?
- Key themes and technology advancements in the biopharma industry that are expected to have the largest (positive and negative) impacts on the industry
- Spotlight on clinical trial technologies: trends of cell and gene therapies, virtual trials and ai used in drug development

12:00pm

- Leveraging data to predict the outlook for 2024 clinical trial outsourcing
- Trends, key players, opportunities and threat in biopharma, focusing on AI, DCTs, cell and gene therapy, etc.
- What the latest investment trends show for small and medium biotechs

Amanda Murphy, Senior Director, Data Intelligence and Solutions, GlobalData

PANEL DISCUSSION: Is DCT old news?

- How we should be thinking about decentralization in the long term
- Hybrid vs decentralized vs traditional clinical trial models: the pros and cons of each
- Which indications and therapeutic areas does DCT have potential in?
- FDA regulations and guidance around DCT
- Incorporating elements of DCT into your clinical trial: is this now commonplace or are we moving away from this?
- Working with vendors and CROs in order to deliver decentralized and hybrid clinical trial

MODERATOR: Christine Hurley,

VP, Clinical Business Operations and Innovation, **Relay Therapeutics**

PANELLISTS: Harry Barnett,
Executive Chairman, Lubris
Biopharma
Mackenzie Johnson, SM, Patient
Centricity, Moderna
Kelly McKee, Vice President, DCTs
and Patient Registries, Medidata

Benchmarking patient enrollment and use of recruitment tactics

- An overview of Tufts CSDD's study on study and site level metrics on patient enrollment effectiveness and site activation rates
- Global recruitment and retention tactics
- Benchmarking results for enrollment and site activation
- Differences and similarities in cycle times and performance across therapeutic areas

Mary Jo Lamberti, Research Associate Professor and Director, Sponsored Research, Tufts Center for the Study of Drug Development



Digitalization in clinical trials: a 360 view Presenting on how to digitalize clinical trials in e.g. endpoints, and study designs Highlighting the possibilities that digital trials bring, whilst moving **Bridging barriers: streamlining** away from the common brick-Assessing risk in your clinical oncology study startup in today's and-mortar sites trial using the Pediatric Risk clinical environment Discussing the rigorous **Assessment Map (PRAM):** Utilizing tactics to attract standards and scientific integrity An interactive, reusable, and enthusiastic sites and PIs required by regulators, whether shareable tool that helps to Mastering the art of streamlined a regular brick-and-mortar trial identify common risks that may contract and budget or a digital trial exist in a pediatric clinical trial negotiations How we tend to focus too much 12:30pm Populates with risk category Optimizing vendor selection and on technology when it's actually and mitigation strategies for oversight the processes for the patients consideration when risk is Implementing best practices for and the sites that matter even identified consistent and committed more Tallies and populates key risks enrollment Major points to consider in and categories identified Nissa Ashenbramer, Senior designing digital trials; building Missy Hansen, Paediatric Strategy Project Manager, Oncology and blocks and practical examples Liaison, ICON PIc Hematology, TFS Health Science to best prepare you to meet the needs of regulators whilst keeping the patient and sites front of mind Sverre Bengtsson, Co-Founder, Senior Vice President Strategic Relations, Viedoc

Lunch and networking break

1:00pm

CASE STUDY: Best practice in managing ongoing relationships with CROs, vendors and other partners Communicating and liaising effectively with CROs: overcoming common challenges Creating and fostering a long 2:00pm term relationship with vendors Balancing levels of vendor oversight in your clinical trial Christine Hurley, Vice President, Clinical Business Operations and Innovation, Relay Therapeutics Emily Matthews, Senior Manager, Clinical Business Operations, Relay **Therapeutics**

PANEL DISCUSSION: The impact and potential of new Al tools in clinical trials

- An overview of how AI and ML are evolving in the pharma industry
- ChatGPT and its potential in supporting clinical trials
- What risks and potential pitfalls are there when using AI?
- Does Al eliminate the need for a human, or is it simply a tool?
- How FDA guidelines impact the use of AI and machine learning in clinical trials

MODERATOR: Vikas Agarwal, VP, Head of Program Development, Greenfire Bio

PANELLISTS: Blake E Wilson, Partner, Hogan Lovells LLP Lisa Kang, Head, Clinical Development Operation, Yoda Pharmaceuticals

Working closely with advocacy groups around clinical trial design

- Key considerations in designing a patient-centric clinical trial
- How to bring the patient voice into your clinical trial design
- Engaging patient advocacy groups from the beginning of your design process and benefits of this

Adrienne Gaggi, Associate Director, Clinical Development, Aldeyra Therapeutics

Continued evolution of cell and gene therapy development programs

- Technology-based development trends
- Driving success in either unexplored settings or in saturated market settings

2:30pm

 Context-dependent stakeholder engagement

Amy Raymond, PhD, PMP, Therapeutic Strategy Lead, Gene Therapy Think Tank, Worldwide Clinical Trials

Re-imagining IRT for modern clinical development

- The majority of clinical studies are being run on technology that is over 10 years old, which limits the ability to innovate and optimally support modern trials
- IRT as a driver of innovation and not a constraint when advances in the technology landscape are applied to allow for more flexible solutions
- Deliver scalable, robust, and future-proof IRT solutions by applying lessons learned from other industries
- Examples include: A.I.-enabled datasets, no-code study deployment, automated excursion reviews, rapid prototyping, reduced (or removed) need for change orders, and ability to adapt to unforeseen challenges

Evan Hahn, Senior Vice President, IRT Solutions, **YPrime**

How do we make participation in clinical research more patient-friendly

- Barriers to patient participation in clinical research
- Pre- and post-pandemic patient expectations
- Balancing the need for robust data collection and reduced patient burden
- What does a potential future hold?

Joyce Moore, Global Head of Patient Engagement, **Allucent**



Sales Enquiry
Nicholas McCudden
Head of OCT Events
T: +61 280 978 126
E: NicholasMcCudden@arenainternational.com

Speaker Enquiry
Louisa Manning
Conference Producer
E: Louisa.Manning@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E: Haida.Amirzadah@arenainternational.com

Designing patient engagement Biomarker opportunities in FiH strategies to inform clinical trial and clinical pharmacology recruitment studies run in an outsourcing Finances and managing your An overview of frameworks model clinical trial budget as a small or developed around patient Introduction: history of "fully medium sized biotech company recruitment and engagement outsourced" studies at Novartis Cutting down your expenses How to best engage patients, Personalized medicine and the without compromising on the caregivers and advocacy shift in clinical trial goals quality of your trial 3:00pm groups in your clinical trial Forecasting and budgeting CRO relationships with design costs for your clinical trial biomarkers Key considerations in ensuring Lessons learned from Solutions in order to ensure your patient recruitment strategy biomarkers your trial budget stays on track is as patient-centric as possible Marilyn Fontaine, Director, Clinical Balancing risks vs benefits Deborah Howe, Director, Global Operations, AnHeart Therapeutics Kathryn Duschean, Senior Patient Recruitment and Scientist, Laboratory Excellence Engagement, Alexion and Operations, Novartis **Pharmaceuticals** 3:30pm Afternoon refreshments and networking break **EXHIBITION APPLE PRIZE DRAW** Visit our exhibitors' booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a 3:50pm chance of winning Apple devices or Amazon vouchers. The Prize Draw will take place in the Exhibition Hall, make sure you don't miss out!

PANEL DISCUSSION: What degree of oversight should you have over your vendors and CRO partners?

- Establishing upfront communication on responsibilities and escalation processes
- What do vendors expect from sponsors in terms of oversight?
- Best practice in building a strong relationship with vendors
- Regulatory guidance for sponsors around vendor communications and oversight: what do you need to be doing as a sponsor?

4:00pm

4:30pm

MODERATOR: John J Seman, CEO, Revitale Pharma

PANELLISTS: Stacey

Oppenheimer, Imaging Vendor
Oversight and Sourcing Strategy
Lead, Pfizer
Shari Coslett, VP, Clinical
Operations, Rhythm
Pharmaceuticals
Shelby Abel-Kilmartin, Director,
Data Management Strategic
Outsourcing and Vendor
Management, Alexion,
AstraZeneca Rare Disease
Leonella Seeley, Associate
Director of Vendor Management
and Operations, Karyopharm

CASE STUDY: Implementing eClinical technology in a medical device setting

- Implementing EDC, CTMS and eTMF for a medical device trial and what benefits these can bring
- Choosing between technology providers: what are the main factors in decision-making?
- Common challenges and hurdles when introducing new systems to your medical device clinical trial
- Considerations for medical device trials compared to drug trials in EDC, CTMS and eTMF

Meredith Frank-Molnia, Senior Director, Clinical Operations, Third Pole Therapeutics

FIRESIDE CHAT: Reducing the burden of clinical trials on patients: what tools are available?

- Culture shift from the inside out: opportunity to briefly immerse yourself in the clinical trial journey from a patient's perspective
- What are the main barriers for patients participating in clinical trials and how can these be minimized?
- Incorporating technology to support patients and increase engagement and retention

INTERVIEWER: Robert Loll,

Senior Vice President, Business Development and Strategic Planning, **Praxis**

INTERVIEWEES: Rohita Sharma, PhD, Global Senior Director, LEAP Lead, Patient Insights and Solutions, Medical Affairs, Alexion Pharmaceuticals

Deborah Howe, Global Patient Recruitment and Engagement, Alexion Pharmaceuticals

Innovative processes to better address today's trial dynamics

Therapeutics

- Supply chain efficiency: why do extra work and spend more money than necessary?
- Payment process efficient: leverage an existing workflow process that sites use everyday
- Understanding the total value a vendor can provide
- Select a vendor that can demonstrate its total value (and

Clarity in the complex: the untapped potential of simulation-based training in clinical research

- Explore the future state of performance-based training
- Discuss how to interpret and apply learning results to optimize and de-risk your study
- Discover how simulation-based training improves study performance

Improving randomization rates with Machine Learning and Al

- Learn the key differences between Machine Learning and Artificial Intelligence for patient recruiting
- Find out why study data is more impactful than patient data on predicting recruitment success
- Discover how to combine your model's results with your business strategy to create reliable recruitment



Sales Enquiry
Nicholas McCudden
Head of OCT Events
T: +61 280 978 126
E: NicholasMcCudden@arenainternational.com

Speaker Enquiry
Louisa Manning
Conference Producer
E: Louisa.Manning@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Marketing Manager
E: Haida.Amirzadah@arenainternational.com

	make you look good in the eyes of your company) Tom Gottschalk, Senior Director, Business Development, Mercalis	David Hadden, President, Founder and Chief Game Changer, Proficiency	Ivor Clarke, Chief Innovation Officer, SubjectWell
 works for your clinical tria Choosing between one if service CRO and working multiple vendors: what a main advantages and disadvantages? Ensuring sponsors, vendous sites are aligned under of shared goal Overcoming challenges communication with vendorder to create strong relationships Siddharth Parulkar, Senior Director, Head of Clinical 	disadvantages? • Ensuring sponsors, vendors and sites are aligned under one shared goal • Overcoming challenges around communication with vendors in order to create strong relationships Siddharth Parulkar, Senior	as a small biotech How specialized should your CRO be in your therapeutic area: is this the most important factor? As a small biotech, what are the benefits of working with a large global CRO vs a small specialized organization? Working with and collaborating with multiple vendors: considerations and best practice Leonella Seeley, Associate Director, Vendor Management and Operations Karvopharm	Working with diverse groups in order to meet achieve DEI in clinical trials How to recruit and engage populations who would not typically participate in clinical trials Ensuring your clinical trial participants are representative of the general population Overcoming common challenges around diversity and inclusion Neha Ghosh, Associate Director, Clinical Research, Fresenius Medical Care

END OF DAY 1 AND NETWORKING DRINKS SPONSORED BY KPS LIFE



Outsourcing in Clinical Trials New England DAY 2 – Thursday 2 nd November				
8:00am	Registration and refreshments			
	Stream A: Clinical Outsourcing and Operations	Stream B: Clinical Technology and Innovation	Stream C: Patient Recruitment and Engagement	
	Chair: Amanda Murphy, Senior Director, Data Intelligence and Solutions, GlobalData	Chair: Jessica Perry, Director, Patient Centricity, Clinical Innovation, Moderna	Chair: Robert Loll, Senior Vice President, Business Development and Strategic Planning, Praxis	
9:00am	Innovating and introducing new technology while ensuring patients remain at the heart of your clinical trial Ensuring any new technology is for the benefit of the patient: the importance of involving the patient voice and advocacy groups in innovation Where are the main difficulties for patients when participating in a clinical trial? Decentralized and remote elements of clinical trials to ease the burden on patients Leticia Tarilonte, Senior Director, Clinical Operations Consultant, Nimbus Therapeutics	PANEL DISCUSSION: How to choose technology vendors for your study • Key questions to ask when selecting clinical trial technology • Building relationships with vendors in order to deliver a seamless and efficient clinical trial • Working with patients and advocacy groups to ensure all new technology is for the ultimate benefit of the patient • Making technology and systems easy for sites to adopt • Balancing cost and opportunity when weighing up benefits of new technology MODERATOR: Jessica Perry, Director, Patient Centricity, Clinical Innovation, Moderna PANELLISTS: Colleen Graham, VP, Clinical Operations, Mediar Therapeutics Christine Hurley, VP, Clinical Business Operations and Innovation, Relay Therapeutics	Patient centricity through health literacy Sponsor funded initiatives that incorporate Health Literacy into the clinical trial lifecycle Beginning patient involvement before the study: building awareness of clinical research The importance of partnership and co-development throughout the research lifecycle Tools and resources available to assist research organizations in effective patient centricity planning Behtash Bahador, Director, Health Literacy, CISCRP	
9:30am	Modernizing site management and monitoring roles to meet the dynamic needs of clinical research The purpose of a Site Manager and how they interact with other monitors on the study to avoid duplicate efforts and contain costs	Find a cure for your complex technology headaches Join Emmes' Chief Innovation Officer, Ching Tian as she addresses how the technology we are accustomed to in clinical trials are getting more complex while not meeting today's clinical research needs. Ching will provide a peek	The importance of scientific validation and data integrity when using accessibility features • FDA recommendation for accessible features and designs to increase clinical trial inclusivity eg zoom in/zoom out functionality	



- When to use a Site Manager for optimal study conduct
- The benefits a Site Manager can bring to studies with highly complex logistics, such as cell and gene therapies or rare disease trials
- How technology drives efficiencies and streamlines communications across the various resources on a study

Nicole Stansbury, Senior Vice President and Head of Global Clinical Operations, Premier Research into a new paradigm of the next-gen solutions with the goal to achieve an 'iphone' like experience. In this session, you will learn:

- How technology is negatively disrupting clinical research
- What a new paradigm needs to look like to turn technology into an enabler for all users
- An example of the next-gen that's already available for use today

Ching Tian, Chief Innovation Officer, **Emmes**

- Importance for patients who may have visual impairments, hearing, motor and dexterity, or cognitive difficulties that may impact inclusivity into clinical trials
- Significance of deploying these functionalities where the drug under study may cause visual impairment such as certain oncology treatments or population under study, eg older adults, may have one or more impairments
- Results of an industry-first clinical study on the ePRO instrument equivalence across accessibility features and patient communication modality preferences

Sarah Tressel Gary, Ph.D., Senior Scientific Advisor, eCOA Clinical Science and Consulting, Clario

PANEL DISCUSSION: Assessing the potential of different geographical regions for running a clinical trial

- Benefits and opportunities of running clinical trials outside of the US including Latin America, Europe, Asia and Australia
- Do the challenges and risks outweigh the benefits of running trials internationally?
- Understanding and navigating clinical trial regulations in different geographical regions

10:00am

 What factors are most important when choosing a location for your clinical trial?

MODERATOR: Harry Barnett, Executive Chairman, Lubris Biopharma

<u>PANELLISTS:</u> Chris Cain, VP, Clinical and Regulatory Affairs, Hyalex Orthopaedics

CASE STUDY: Revolutionizing drug delivery devices: paving the way for clinical success

- Overview: the potential from using nose-to-brain technology to treat complex CNS disorders
- Learnings and outcomes from running a clinical trial on a drug delivery device
- Advancing treatment for neurogenerative diseases: how Kurve is reshaping this

David Sherris, Board Member, Kurve Therapeutics

CASE STUDY: Recruiting for a rare disease trial

- Identifying eligible patients for an orphan drug trial: designing your recruitment campaign
- Best practice in collaborating with patient advocacy groups for rare diseases
- The role of social media and other online tools to drive patient recruitment for a rare disease trial

Christine Slater, Associate
Director, Patient Recruitment,
Editas Medicine
Dima Hendricks, Sickle Cell
Patient Advocate



	Kelsey Miller, Director, Clinical Development, Intrinsic Therapeutics Judith Murphy, ED, Centralized Contracting and Outsourcing, Kura Oncology Donna Fraser, Director, Client Operations, Novotech			
10:30am	Morning refreshments and networking break			
11:00am	Strengthening the CRO/sponsor relationship: a deep dive into studies • Maintaining and tracking the CRO/sponsor partnership • Exploring tools and metrics that can be put in place • How best to utilize these in order to strengthen partnerships with CROs to ensure trial success Rana Said, Biomarker Study Coordinator, Novartis	Innovating your data management strategy: how to stay ahead of the curve • Developing efficient infrastructures and processes for clinical data management • Navigating changing regulatory requirements around data in clinical trials • Key drivers for innovation: considerations for 2024 Holly Huang, Vice President, Head of Biometrics, Denovo Biopharma	Engaging patients in a rare disease clinical trial How rare disease trials are unique when it comes to building and fostering relationships with patients Reasons and tactics to engage longitudinally with rare disease patients Working with patients, carers and advocacy groups for a successful patient engagement strategy Nan Doyle, Patient Advocate	
11:30am	An agile approach to PBMC collection in vaccine trials Critical aspects of PBMC processing in the context of clinical trials Challenges of sample handling flows Importance of consistent isolation protocols Main quality control aspects of PBMC handling Upscaling capacity planning for sample collection Importance of accessibility to an established global network Mike Waters, Global Vice President Biopharma Business Development, Cerba Research	The importance of real-time forecasting in biotech trials Review the challenges of forecasting clinical trial costs and its impact on cash flow Understand how a data-driven and automated approach can produce more accurate forecasts quickly Learn how a biotech company can apply these methodologies Stuart Thiede, Vice President and General Manager, Clinical Trial Payments, IQVIA Technologies	 The innovations of decentralized clinical trials Decentralized clinical trial numbers grow and are forecast to continue, even after the accelerated adoption driven by the Covid-19 global pandemic A view on the next steps of innovations within decentralized clinical trials Why "consumerisation of clinical trials" continues to be key when considering patient centricity How multi-channel data collection is at the heart of clinical trials – and the need to integrate data sources to maximise the value of this powerful by-product of decentralised clinical trial methodologies Tola Olorunnisola, Senior Vice President, Clinical Services and 	



Strategy, Avantor

Revolutionizing clinical trials with accelerating clinical Utilizing technology to accelerate CASE STUDY: Running a clinical evidence models clinical trial enrolment trial when repurposing an Novel approaches for drug Kevin will be sharing his experience existing drug approvals with accelerated An overview of benefits, of using tools such as a patient approval pathway to challenges and key engagement website, a strategic streamline processes considerations in drug partnership and social media to Enhancing collaboration repurposing clinical trials impact patient enrolment across the between the FDA and CMS in 12:00pm FDA regulations and guidance portfolio of Biogen clinical trials. developing new payment when it comes to drug Join him to hear more about how to methods for drugs approved repurposing optimize your patient enrolment, via accelerated approval Utilizing existing safety studies with Kevin's top tips and lessons Improving patient access to to speed up your trial timeline learned. post-market safety and John J Seman, Chief Executive Kevin Ahonen, Former Head of Officer, Revitale Pharma efficacy data Digital Engagement, Biogen Blake Edward Wilson, Partner (FDA Regulatory), Hogan Lovells 12:30pm Lunch and networking break Chair: Robert Loll, Senior Vice President, Business Development and Strategic Planning, Praxis Operating conditions and trends impacting global clinical trial performance Review macro-level drug development trends Characterize the current operating environment for planning and executing clinical trials 1:30pm Discuss underlying drivers of inefficiency and poor performance Explore new strategies to address and counter the effect of underlying drivers Ken Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development, Tufts **University School of Medicine** Forging the future with CTMS Clinical trials play a crucial role in medical advancements. With increasing challenges, it is essential for our tools to adapt. CTMS represents a significant step forward in how we manage these trials, and by utilizing it effectively, 2:15pm we can improve the healthcare landscape for everyone.



Hope Weisser, Senior Product Manager, TransPerfect

April Mattison-Wolfe, Senior Solutions Architect, TransPerfect

KEYNOTE PANEL DISCUSSION: Where can we expect clinical trials to be in 2024? How will new and upcoming regulations affect clinical trials, and how can sponsor companies best navigate The impact of emerging AI tools such as ChatGPT on clinical trials: are these a challenge or an opportunity? Should we still be discussing decentralization as a long term clinical trial model? Where are the primary opportunities to make clinical trial participation easier on patients and thus improve recruitment, engagement and retention? 2:45pm MODERATOR: Amanda Murphy, Senior Director, Data Intelligence and Solutions, GlobalData **PANELLISTS:** Hollie Schmidt, Vice President, Scientific Operations, Accelerated Cure Project for MS Prasanna Rao, Senior Director, Global Head of Al and ML, Pfizer Rinaldo Dorman, MBA, CPSM, Associate Director, R&D Global Procurement & Strategic Sourcing, Sarepta **Therapeutics** Behtash Bahador, Director, Health Literacy, CISCRP 3:15pm Afternoon refreshments and networking break **EXHIBITION APPLE PRIZE DRAW** Visit our exhibitors' booths throughout the conference and collect stamps in order to enter our Prize Draw and be 3:35pm in for a chance of winning Apple devices or Amazon vouchers. The Prize Draw will take place in the Exhibition Hall, make sure you don't miss out! PROBLEM-SOLVING ROUNDTABLE DISCUSSIONS During the roundtable discussion session, the conference hall will be divided into three 'zones'. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within clinical operations. Roundtables will take place in the Stream B conference room. ROUNDTABLE 1: US vs international CROs: which is best for your trial? Vikas Agarwal, Vice President, Head of Program Development, Greenfire Bio 3:45pm **ROUNDTABLE 2: Managing clinical trial budgets effectively** Marilyn Fontaine, Director, Clinical Operations, AnHeart Therapeutics ROUNDTABLE 3: Delivering large and complex clinical trials with cross functional teams Jenny Bentsen Gordon, Vice President, Head of Clinical Operations, Editas Medicine ROUNDTABLE 4: Maximizing your CRO relationship and building a solid partnership Ritu Mehta, Director, Business Development, DP Clinical Douglas Henry, President, Phazemos

END OF CONFERENCE



Chairperson's closing remarks

5:00pm